BREAKWATER: New Standard of Care Frontline Regimen for BRAF V600E-Mutant mCRC

Christopher Lieu, MD, of University of Colorado Medicine, discusses the BREAKWATER trial presented at ASCO GI 2025, which examined encorafenib and cetuximab with FOLFOX versus SOC chemotherapy in patients with BRAF V600E-mutant metastatic colorectal cancer.

With an overall survival rate of about 80%, he examines how the combination may serve as a new FDA-approved frontline regimen for this disease.